Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Comment Examples

Our submitted comments

DiMe responds to request for comments to future telehealth coverage and payment policy

February 10, 2023

View DiMe Comment

DiMe Responds to Request for Information Regarding Emergency Clinical Trials

January 19, 2023


View DiMe Comment

FDA Diversity Plan Clinical Trials

A letter submitted on behalf of the Digital Medicine Society (DiMe) for consideration by the U.S. Food and Drug Administration (FDA) regarding Docket No. FDA-2021-D-0789 for “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability .”

June 2022

View DiMe Comment

Using Digital Health Technologies in Remote Data Acquisition in Clinical Investigations

The DiMe community, as leading experts in digital measurement, responded to the FDA draft guidance with support and suggestions.

March 2022

View DiMe Comment

DiMe responds to the White House OSTP RFI on DHTs

On behalf of the DiMe community, we submitted a response to the White House Office of Science and Technology Policy (OSTP) RFI highlighting the power of DiMe’s multi-stakeholder, interdisciplinary program delivery model to transform community health, individual wellness, and health equity. Connected community health requires meeting the needs of the community through services and improved knowledge for the community and those working with them. 

February 2022

View DiMe Comment

Building Trust In the Health Data Ecosystem

Executive Director Jen Goldsack asserts that in order to ensure the success of Cures 2.0, provisions must be added that bolster public trust in how health data are used.

July 2020

View DiMe Comment

Letter to Congress urging action on telehealth

DiMe urges action from congress to make telehealth flexibilities created during the COVID-19 pandemic permanent

June 29th, 2020

View DiMe Comment

Modernizing FDA’s Data Strategy

The FDA acknowledges that a large gap separates important scientific advances and the technologies needed to translate those advances into new therapies for patients and new ways to protect the public health. DiMe comments on how the evidence base for the safety and effectiveness of these new products has not kept pace with their development.

April 30th, 2020

View DiMe Comment

Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease-2019 (COVID-19) Public Health Emergency

The FDA issued a guidance to leverage non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact and exposure to COVID-19 during this pandemic. DiMe provided a public comment.

April 14th, 2020

View DiMe Comment

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency

This FDA guidance provides general considerations to assurance the safety of trial participants, maintaining compliance with good clinical practice, and minimizing risks to trial integrity during COVID-19.

April 21st, 2020

View DiMe Comment

Request for Information (RFI)*



Healthcare System/Clinicians

* We selected these examples to provide a range of perspectives and approaches used in Federal Comments. Their inclusion here does not indicate DiMe’s endorsement.

Sign up to receive our monthly updates

Engage with the dime community on slack

USING A DIME RESOURCE? Share your story

Contact Us

Copyright ©2023 The Digital Medicine Society (DiMe). All Rights Reserved.